JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Cintirorgon (formerly also known as LYC55716), a novel and potent immune modulatory medicine developed by Lycera, is a synthetic and orally bioavailable small molecule agonist of RAR-related orphan receptor gamma (RORgamma). It combines multiple anti-tumor mechanisms into a single therapeutic by modulating gene expression to reprogram immune cells for improved function, as well as decrease immunosuppressive mechanisms. In January 2018, Lycera announced the initiation of a multi-center Phase 1B combination study in patients with advanced, relapsed, or refractory solid tumors such as metastatic Non-Small Cell Lung Cancer in combination with pembrolizumab.
References: 2018 ASCO-SITC Clinical Immuno-Oncology Symposium (Poster); Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors
Related CAS #: 2055538-47-9 (sodium salt) 2055536-64-4 (free acid)
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!